Evidence map›Paper›PMID 42758777›Full record

ArticlePloS one2026

A microbiome-metabolome signature associated with pediatric severe asthma.

Mélanie Briard, Blanche Guillon, Eric Venot, Marta Grauso, Christelle Hennequet-Antier, Aurélia Bruneau, François Fenaille, Florence Castelli, Muriel Thomas, Guillaume Lezmi and 3 more

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mélanie BriardUniversité Paris-Saclay, CEA, INRAE, UMR Département Médicaments et Technologies pour la Santé (DMTS)/SPI/Laboratoire d'Immuno-Allergie Alimentaire, Gif-sur-Yvette, France.
Blanche GuillonUniversité Paris-Saclay, CEA, INRAE, UMR Département Médicaments et Technologies pour la Santé (DMTS)/SPI/Laboratoire d'Immuno-Allergie Alimentaire, Gif-sur-Yvette, France.
Eric VenotUniversité Paris-Saclay, CEA, INRAE, UMR Département Médicaments et Technologies pour la Santé (DMTS)/SPI/Laboratoire d'Immuno-Allergie Alimentaire, Gif-sur-Yvette, France.
Marta GrausoUniversité Paris-Saclay, CEA, INRAE, UMR Département Médicaments et Technologies pour la Santé (DMTS)/SPI/Laboratoire d'Immuno-Allergie Alimentaire, Gif-sur-Yvette, France.
Christelle Hennequet-AntierINRAE, Université Paris-Saclay, BioinfOmics, MIGALE Bioinformatics Facility, Jouy-en-Josas, France.ORCID https://orcid.org/0000-0001-5836-2803
Aurélia BruneauUniversité Paris-Saclay, INRAE, AgroParisTech, UMR1319 Micalis Institute, Jouy-en-Josas, France.
François FenailleUniversité Paris-Saclay, CEA, INRAE, UMR Département Médicaments et Technologies pour la Santé (DMTS)/SPI/Laboratoire innovations en spectrométrie de masse pour la santé, MetaboHUB, Gif-sur-Yvette, France.ORCID https://orcid.org/0000-0001-6787-4149
Florence CastelliUniversité Paris-Saclay, CEA, INRAE, UMR Département Médicaments et Technologies pour la Santé (DMTS)/SPI/Laboratoire innovations en spectrométrie de masse pour la santé, MetaboHUB, Gif-sur-Yvette, France.
Muriel ThomasUniversité Paris-Saclay, INRAE, AgroParisTech, UMR1319 Micalis Institute, Jouy-en-Josas, France.ORCID https://orcid.org/0000-0002-7608-3274
Guillaume LezmiAP-HP, Hôpital Necker-Enfants Malades, Service de Pneumologie et Allergologie Pédiatriques, Paris, France.
Maria Leite-de-MoraesUniversité Paris Cité, Institut Necker Enfants Malades, Equipe Immunorégulation et Immunopathologie, Inserm UMR1151, CNRS, Paris, France.ORCID https://orcid.org/0000-0002-2891-2269
Karine Adel-PatientUniversité Paris-Saclay, CEA, INRAE, UMR Département Médicaments et Technologies pour la Santé (DMTS)/SPI/Laboratoire d'Immuno-Allergie Alimentaire, Gif-sur-Yvette, France.
Vinciane Saint-CriqUniversité Paris-Saclay, INRAE, AgroParisTech, UMR1319 Micalis Institute, Jouy-en-Josas, France.ORCID https://orcid.org/0000-0003-0042-3735

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere asthma is a heterogeneous condition encompassing multiple phenotypes. Understanding lung-specific mechanisms in children with severe asthma may enable the development of more precise therapeutic strategies. We previously reported that immune components in bronchoalveolar lavages (BALs) differentiate children with severe asthma from non-asthmatic disease-controls and, frequent from non-frequent exacerbators, among children with severe asthma.

objectiveTo identify a local signature of severe asthma using complementary multi-omics analyses of BALs. A secondary objective was to evaluate whether bacterial taxa and metabolites discriminate severe asthma subtypes associated with distinct phenotypes or endotypes.

methodsBAL microbiome and metabolome were investigated in 20 children with severe asthma and 10 non-asthmatic children using 16S rRNA gene amplicon sequencing and liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS), respectively. Data were analysed separately and through integrative multi-omics approaches.

resultsCompared with controls, BALs from children with severe asthma showed increased alpha-diversity, higher relative abundances of Actinobacteriota, Streptococcus, Moraxella, Corynebacterium, Tropheryma, and Treponema, and an altered polyamine pathway characterized by reduced arginine and increased spermine and spermidine levels. Integrated analyses revealed significant associations between Streptococcus and both spermine and spermidine. Independently, each dataset discriminated severe asthma phenotypes, notably exacerbation frequency and co-occurring atopic dermatitis. Unsupervised clustering of microbiome profiles identified four distinct clusters that may reflect severe asthma endotypes.

conclusionsThis study identifies a distinct airway microbiome-metabolome signature associated with pediatric severe asthma. Enrichment of specific bacterial taxa, particularly Streptococcus, together with altered polyamine metabolic pathway, highlights microbial-metabolic interactions potentially involved in disease pathophysiology. The ability of microbiome and metabolome profiles to independently and jointly discriminate clinical phenotypes underscores the relevance of multi-omics approaches for diagnosis and follow-up of severe asthma. Our findings support the importance of airway-level profiling to improve mechanistic understanding of severe asthma and inform on future targeted therapeutic strategies.

Indexed as

AsthmaMetabolomeMicrobiotaAdolescentBronchoalveolar Lavage FluidCase-Control StudiesChildFemaleHumansMaleMultiomicsRNA, Ribosomal, 16SSeverity of Illness IndexRNA, Ribosomal, 16S

Identifiers

PMID42758777
PMCPMC13588362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.